A series of xanthene-3-ones derivatives which were synthesized by us was tested for the antiplatelet activity. Initial screening showed that a majority of the synthesized derivatives had substantial antiplatelet potential.
None of the compounds were able to block cyclooxygenase 1 or thromboxane synthase. The mechanism appeared to be based on antagonism of thromboxane effects.
The most potent compound 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one had better potential to block collagen induced platelet aggregation than clinically used acetylsalicylic acid.